Multivariant Covid-19 vaccine booster shows promise, early trial data suggests

A Covid vaccine booster aimed at tackling multiple variants shows promise in inducing a comprehensive immune response, early data suggests. The first results of a phase one trial, launched in Manchester in September 2021, reveal the jab has strong levels of neutralising antibodies. They are similar to approved mRNA vaccines (like Pfizer BioNTech and Moderna), but at up to a 10-fold lower dose in the first 10 individuals, the research indicates.